Drug intelligence / Profile preview

RSV Vaccine (CHO cell-derived VLP)

Development stage: Unknown
Lead developer: Grand Theravac Life Science Nanjing
Modality: Split/Subunit Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Cancer Vaccines → Therapeutic Vaccines → Vaccines & Immunotherapeutics, Recombinant Protein Vaccines → Recombinant Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics
Administration: Intramuscular

Overview

RSV Vaccine (CHO cell-derived VLP) is a virus-like particle (VLP) vaccine candidate developed by Grand Theravac Life Sciences for the prevention of respiratory syncytial virus (RSV) infection. Produced using a Chinese Hamster Ovary (CHO) cell expression platform, the vaccine consists of non-infectious particles that mimic the structural characteristics of the native virus. This approach is designed to present viral antigens in a highly immunogenic, repetitive array to the immune system, thereby eliciting a robust protective response without the risks associated with live-attenuated or inactivated virus vaccines. The candidate has received Investigational New Drug (IND) approval, marking its transition into clinical evaluation.

Other names: respiratory syncytial virus vaccine (CHO cell-derived VLP)RSV VLP vaccine

Beyond the preview

Go deeper on RSV Vaccine (CHO cell-derived VLP).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on RSV Vaccine (CHO cell-derived VLP).

Explore the full profile